How would you lead a goals of care discussion in terms of prognosis/survival likelihood for patients with inotropic dependent HFrEF with CRT-D on maximally tolerated GDMT? 

I usually start by reviewing the prognosis with inotrope-dependent HF, quote data from DT VAD trials (REMATCH). I assess the eligibility for DT VAD and transplantation and review the shared decision-making pathways (IDECIDE LVAD) if the patient is eligible for DT VAD.

If the patient is not a candida...

In addressing the nuanced management and prognosis for patients with inotrope-dependent heart failure with reduced ejection fraction (HFrEF), recent scholarly discussions and research findings offer a comprehensive view that aligns with and expands upon the insights shared by esteemed experts Drs. @...